Jeremy Duvall

Jeremy Duvall

Company: Mersana Therapeutics

Job title: Associate Director Chemistry

Seminars:

Panel Discussion: Rationale, Progress and Development of STING & TLR-Targeted Therapies 9:00 am

Harnessing the innate immune system and local immunological microenvironment Shaping tumor immunogenicity Priming responses to checkpoint blockade – the relative importance of these pathways in regulating antitumor immunity and responsiveness to checkpoint blockade (PD-1, PD-L1, CTLA-4 inhibitors) Identifying clinical indications that are sensitive to innate immune stimulatory approaches (e.g. beyond melanoma) Challenges and opportunities in…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.